An orally-available monovalent SMAC mimetic compound as a broad-spectrum antiviral

Miao Mei , Maria_Antonietta Impagnatiello , Jun Jiao , Ulrich Reiser , Ulrike Tontsch-Grunt , Ju Zhang , Paul Nicklin , Bingke Yu , Yu Wang , Yuan He , Xu Tan

Protein Cell ›› 2024, Vol. 15 ›› Issue (1) : 69 -75.

PDF (181737KB)
Protein Cell ›› 2024, Vol. 15 ›› Issue (1) : 69 -75. DOI: 10.1093/procel/pwad033
LETTER

An orally-available monovalent SMAC mimetic compound as a broad-spectrum antiviral

Author information +
History +
PDF (181737KB)

Cite this article

Download citation ▾
Miao Mei, Maria_Antonietta Impagnatiello, Jun Jiao, Ulrich Reiser, Ulrike Tontsch-Grunt, Ju Zhang, Paul Nicklin, Bingke Yu, Yu Wang, Yuan He, Xu Tan. An orally-available monovalent SMAC mimetic compound as a broad-spectrum antiviral. Protein Cell, 2024, 15(1): 69-75 DOI:10.1093/procel/pwad033

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther 2014;144:82–95.

[2]

Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J Transl Med 2020;18:390.

[3]

Clark MP, Huynh T, Rao S et al. Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models. Cell Death Dis 2021;12:641.

[4]

Ebert G, Allison C, Preston S et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci USA 2015;112:5803–5808.

[5]

Ladner SK, Otto MJ, Barker CS et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997;41:1715–1720.

[6]

Li G, Zhu Y, Shao D et al. Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model. Hepatology 2018;67:56–70.

[7]

Maini MK, Boni C, Lee CK et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269–1280.

[8]

Mei M, Tan X. Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci 2021;8:671263.

[9]

Molyer B, Kumar A, Angel JB. SMAC mimetics as therapeutic agents in HIV infection. Front Immunol 2021;12:780400.

[10]

Pache L, Dutra MS, Spivak AM et al. BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe 2015;18:345–353.

[11]

Pache L, Marsden MD, Teriete P et al. Pharmacological activation of non-canonical NF-kappaB signaling activates latent HIV-1 reservoirs in vivo. Cell Rep Med 2020;1:100037.

[12]

Petersen SL, Wang L, Yalcin-Chin A et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007;12:445–456.

[13]

Xiang C, Du Y, Meng G et al. Long-term functional maintenance of primary human hepatocytes in vitro. Science 2019;364:399–402.

[14]

Yang PL, Althage A, Chung J et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002;99: 13825–13830.

RIGHTS & PERMISSIONS

The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.

AI Summary AI Mindmap
PDF (181737KB)

283

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/